Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 4
2005 5
2006 1
2007 10
2008 8
2009 1
2010 9
2011 14
2012 9
2013 6
2014 2
2015 5
2016 5
2017 5
2018 1
2019 5
2020 3
2021 7
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Tesamoreli
Page 1
Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease.
Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M. Fraile JM, et al. Drug Des Devel Ther. 2021 Sep 22;15:3997-4009. doi: 10.2147/DDDT.S315724. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34588764 Free PMC article. Review.
Obeticholic acid (Intercept Pharmaceuticals), Cenicriviroc (Allergan), Aramchol (Galmed Pharmaceuticals), Resmetirom (Madrigal Pharmaceuticals), Dapagliflozin and Semaglutide (Novo Nordisk) are in advanced Phase 3 clinical trials, while Belapectin (Galectin Therapeutics), MSDC-06 …
Obeticholic acid (Intercept Pharmaceuticals), Cenicriviroc (Allergan), Aramchol (Galmed Pharmaceuticals), Resmetirom (Madrigal Pharmaceutica …
Tesamorelin.
[No authors listed] [No authors listed] 2018 Oct 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Oct 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644039 Free Books & Documents. Review.
Tesamorelin is a synthetic growth hormone releasing hormone analogue used in the treatment of visceral adiposity in human immunodeficiency virus (HIV) infected patients with lipodystrophy. Tesamorelin is given subcutaneously and has major effects on glucose and lipi …
Tesamorelin is a synthetic growth hormone releasing hormone analogue used in the treatment of visceral adiposity in human immunodefic …
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.
Dhillon S. Dhillon S. Drugs. 2011 May 28;71(8):1071-91. doi: 10.2165/11202240-000000000-00000. Drugs. 2011. PMID: 21668043 Review.
This article reviews the pharmacological properties, clinical efficacy and tolerability of tesamorelin in patients with HIV-associated central fat accumulation. ...Tesamorelin was generally well tolerated, with treatment-emergent serious adverse events occurring in …
This article reviews the pharmacological properties, clinical efficacy and tolerability of tesamorelin in patients with HIV-associate …
Pharmacoeconomic Review Report: Tesamorelin (Egrifta).
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. PMID: 30896905 Free Books & Documents. Review.
Tesamorelin (Egrifta) is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference 95 cm for males and 94 cm for females, and confirmed by a VAT level > 130 cm(2) by computed tomography (CT) scan, in treatment-experienced ad …
Tesamorelin (Egrifta) is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference 95 c …
Spotlight on tesamorelin in HIV-associated lipodystrophy.
Dhillon S. Dhillon S. BioDrugs. 2011 Dec 1;25(6):405-8. doi: 10.2165/11208290-000000000-00000. BioDrugs. 2011. PMID: 22050344 Review.
This article reviews the pharmacological properties, clinical efficacy and tolerability of tesamorelin in patients with HIV-associated central fat accumulation. ...Tesamorelin was generally well tolerated, with treatment-emergent serious adverse events occurring in …
This article reviews the pharmacological properties, clinical efficacy and tolerability of tesamorelin in patients with HIV-associate …
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.
Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, Pan CS, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Stanley TL, Chung RT, Grinspoon SK. Fourman LT, et al. JCI Insight. 2020 Aug 20;5(16):e140134. doi: 10.1172/jci.insight.140134. JCI Insight. 2020. PMID: 32701508 Free PMC article. Clinical Trial.
As such, tesamorelin is the first strategy that has shown to be effective against NAFLD among the population with HIV. ...Notably, among tesamorelin-treated participants, these changes in hepatic expression correlated with improved fibrosis-related gene score. ...
As such, tesamorelin is the first strategy that has shown to be effective against NAFLD among the population with HIV. ...Notably, am …
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.
Spooner LM, Olin JL. Spooner LM, et al. Ann Pharmacother. 2012 Feb;46(2):240-7. doi: 10.1345/aph.1Q629. Epub 2012 Jan 31. Ann Pharmacother. 2012. PMID: 22298602 Review.
All studies relevant to the evaluation of efficacy and safety of tesamorelin in the management of HIV-associated lipodystrophy were included, with a focus on trials completed in humans. ...Both studies had 26-week extension phases that confirmed maintenance of VAT improvem …
All studies relevant to the evaluation of efficacy and safety of tesamorelin in the management of HIV-associated lipodystrophy were i …
Tesamorelin.
Grunfeld C, Dritselis A, Kirkpatrick P. Grunfeld C, et al. Nat Rev Drug Discov. 2011 Feb;10(2):95-6. doi: 10.1038/nrd3362. Nat Rev Drug Discov. 2011. PMID: 21283099
In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy....
In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by th …
Clinical Review Report: Tesamorelin (Egrifta).
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug. PMID: 30920787 Free Books & Documents. Review.
Excess VAT negatively affects patients' body image and quality of life (QoL). Tesamorelin is a synthetic analogue of growth hormone-releasing factor that triggers diverse metabolic effects, including lipolysis. The objective of this systematic review was to evaluate the be …
Excess VAT negatively affects patients' body image and quality of life (QoL). Tesamorelin is a synthetic analogue of growth hormone-r …
Tesamorelin improves fat quality independent of changes in fat quantity.
Lake JE, La K, Erlandson KM, Adrian S, Yenokyan G, Scherzinger A, Dubé MP, Stanley T, Grinspoon S, Falutz J, Mamputu JC, Marsolais C, McComsey GA, Brown TT. Lake JE, et al. AIDS. 2021 Jul 15;35(9):1395-1402. doi: 10.1097/QAD.0000000000002897. AIDS. 2021. PMID: 33756511 Free PMC article.
Baseline characteristics were similar across arms, including VAT (-91 HU both arms, P = 0.80) and SAT density (-94 HU tesamorelin, -95 HU placebo, P = 0.29). Over 26 weeks, mean (SD) VAT and SAT density increased in tesamorelin-treated participants only [VAT: +6.2 ( …
Baseline characteristics were similar across arms, including VAT (-91 HU both arms, P = 0.80) and SAT density (-94 HU tesamorelin, -9 …
105 results